Compare Amphastar Pharmaceuticals Inc (AMPH) vs CAVA Group Inc (CAVA) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

CAVA Group trades at $72.18, up 5.84% in the last session, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported Q1 2026 EPS of $0.20, beating expectations, and revenue growth to $1.18 billion in 2025. Analyst sentiment remains strongly positive with 72% buy ratings and a consensus price target of $94.19, though high valuation multiples like a P/E of 138.81 signal premium pricing. Recent news highlights expansion and innovation efforts.

Outlook: CAVA's growth trajectory and analyst optimism support upside potential, but elevated valuations and margin pressures pose risks. Investment opportunity lies in continued expansion and market share gains, while risks include competitive intensity and execution challenges in scaling operations.